Insights On Enterprise Solutions
-
Alofisel P3 Cell Therapy Facility
2/21/2024
Despite various issues with a client's CQV project, CAI delivered the project on time and significantly contributed to the delivery of the first ATMP facility in Ireland.
-
Commercial Vs. Technical Priorities: The PM High-Wire Act
2/21/2024
PMs must be technically adept enough to understand a project, but their main role is to ensure it delivers in terms of scope and budget.
-
Bioprocess Solutions: Advancements With Single-Use Technology
2/15/2024
The integration of single-use technologies in upstream and downstream bioprocessing stages has transformed bioprocess manufacturing by improving efficiency, reducing costs, and minimizing contamination risks.
-
Building Better BioTherapeutics Using Machine Learning And Synthetic Biology
2/14/2024
Learn about high throughput biologic automation and GMP master cell banking services as well as variable selection services that search the SQL space to find promoters.
-
Pros And Cons Of Outsourcing To Taiwan: What You Need To Know
2/14/2024
Businesses adopt outsourcing to Asia as a pivotal strategy. While this entails both benefits and drawbacks, explore why teams should first necessitate careful consideration before making a decision.
-
Current Trends And Innovations In The Development Of ADCs
2/14/2024
Learn the current innovations and trends in the development of ADCs focusing on three main aspects: linker technology, drug payloads, and manufacturing.
-
Shelf Lives & Logistics: Ensuring The Stability Of Therapeutic Cancer Vaccines
2/13/2024
In this segment of the Bioprocess Online Live event, guest experts Peter Berglund, chief scientific officer at HDT Bio, Johanna Kaufmann, EVP for oncology at Codagenix, and Robert Georgantas, president and CTO at Providence Therapeutics take audience questions regarding the stability and portability of therapeutic cancer vaccines.
-
Manufacturing Challenges In Cancer Vaccine Development
2/13/2024
From LNP stability to outsourced manufacturing capacity, there’s no shortage of challenges to developing and manufacturing both viral and RNA-based therapeutic vaccines. In this segment of the Bioprocess Online Live event, guest experts Peter Berglund, chief scientific officer at HDT Bio, Johanna Kaufmann, EVP for oncology at Codagenix, and Robert Georgantas, president and CTO at Providence Therapeutics address those challenges, and our audience’s questions about them.
-
Boost Drug Development Productivity With Contract Research Services
2/13/2024
Find out how organ-on-a-chip contract research services are enabling the pharmaceutical industry to overcome the largest challenge in drug development—Eroom’s Law.
-
Consolidating The Supply Chain For mRNA
2/12/2024
Learn about the first end-to-end cGMP facility that was developed for mRNA manufacturing to address the shortage of CDMOs and the inadequate and inefficient supply chain options for sourcing GMP mRNA.